Biopharma AI
By
Is Merck’s WINREVAIR Set to Redefine First-Year PAH Treatment? Phase 3 HYPERION Results Show Over 70% Clinical Event Risk Reduction in Newly Diagnosed Patients
Key Takeaways:• Game-Changing Efficacy: WINREVAIR™ (sotatercept-csrk) cut clinical worsening risk in PAH by a statistically significant margin in…
Can Sanofi’s Sarclisa-VRd Regimen, Backed by EMA’s CHMP, Redefine Frontline Standards in Transplant-Eligible Multiple Myeloma?
Key Highlights EMA’s CHMP Endorses Sarclisa-VRd for Frontline Multiple Myeloma in Transplant-Eligible AdultsOn June 23, 2025, Sanofi announced…
Could Lilly’s Oral GLP-1 Orforglipron Revolutionize Type 2 Diabetes Treatment? Complete Phase 3 Results Show Compelling Efficacy and Safety on Par with Injectable GLP-1 Therapies
Key Highlights Orforglipron Delivers Clinically Meaningful Glycemic and Weight ImprovementsThe ACHIEVE-1 Phase 3 trial established orforglipron’s efficacy, showing…
How Caris Life Sciences’ $7.6B IPO the Breakout Moment for AI-Powered TechBio in Oncology and Beyond?
Key Highlights AI Meets Molecular Medicine: A New TechBio Contender EmergesCaris Life Sciences’ successful IPO positions it as…
Could AbbVie and IGI’s $1.9B Bet on AI-Engineered Trispecific Antibody Signal a New Era for Relapsed Myeloma Treatment?
Key Highlights: AbbVie Accelerates into AI-Powered Immuno-OncologyAbbVie has entered a global licensing agreement worth up to $1.925 billion…
Will AI-Powered Querent™ by Mango Sciences Transform Veeda Lifesciences’ Global Clinical Trial Efficiency?
Key Highlights AI-Driven Precision in Global Trial RecruitmentVeeda Lifesciences, a global CRO, has announced a strategic investment in…
